Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(7):E1; doi:10.1093/jnci/dji125
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kober, T.
Right arrow Articles by Engert, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kober, T.
Right arrow Articles by Engert, A.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

ONLINE COMMENTARY

Second Biannual Report of the Cochrane Haematological Malignancies Group

Thilo Kober, Julia Bohlius, Sven Trelle, Andreas Engert

Affiliations of authors: Cochrane Haematological Malignancies Group, Cologne, Germany (TK, JB, ST, AE); Department of Internal Medicine I, University of Cologne, Germany (JB, ST, AE).

Correspondence to: Thilo Kober, MNA, Level 4 (Neubau), Department of Internal Medicine I, University Hospital Cologne, Kerpener Str. 62, Cologne, 50924, Germany (e-mail: thilo.kober@medizin.uni-koeln.de).

The first 150 words of the full text of this article appear below.


   INTRODUCTION
 
This second biannual report features again new Cochrane reviews and protocols, as well as a series of recently published randomized controlled trials. The structure of the report remains largely unchanged, thus providing a summary of the latest systematic reviews and protocols produced by the Cochrane Haematological Malignancies Group (CHMG), followed by an overview of key features of recently published clinical trials in the field of hemato-oncology. Ongoing trials were not considered this time. The guiding principles for study selection were implication for clinical practice, methodological aspects, and timeliness. An electronic search of the Ovid Medline database (http://gateway.ut.ovid.com) was undertaken on 10 November 2004 and 5 January 2005. From 160 identified studies, eight randomized controlled trials were selected covering the publication period from January 2004 to December 2004. These summaries are aimed to assist the busy medical practitioner in the clinical decision-making for the benefit of patients under their . . . [Full Text of this Article]


   COCHRANE REVIEWS AND PROTOCOL
 
CHMG Reviews

Clinical background. Contribution. Implications for practice. Clinical background. Contribution. Implications for practice. CHMG Protocols


   PUBLISHED TRIALS
 
Hodgkin Lymphoma

Clinical background. Contribution. Implications for practice. Most interesting features. Key study features are as follows. Indolent Non-Hodgkin Lymphoma

Clinical background. Contribution. Implications for practice. Most interesting features. Key study features are as follows. Indolent and Aggressive Non-Hodgkin Lymphoma

Clinical background. Contribution. Implications for practice. Most interesting features. Key study features are as follows. Clinical background. Contribution. Implications for practice. Most interesting features. Key study features are as follows. Acute Myeloid Leukemia

Clinical background. Contribution. Implications for practice. Most interesting features. Key study features are as follows. Acute Lymphoblastic Leukemia

Clinical background. Contribution. Implications for practice. Most interesting features. Key study features are as follows. Stem Cell Transplantation

Clinical background. Contribution. Implications for practice. Most interesting features. Key study features are as follows. Supportive Care

Clinical background. Contribution. Implications for practice. Most interesting features. Key study features are as follows. Other Published Trials of Potential Interest

A Plea for CONSORT


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Biannual Report of the Cochrane Haematological Malignancies Group
Sven Trelle, Gail Higgins, Thilo Kober, and Andreas Engert
J Natl Cancer Inst 2004 96: E2. [Extract] [Full Text]